Sarcoma surgeon and scientist Samuel Singer is the Director of Memorial Sloan Kettering’s Sarcoma Center.
The Sarcoma Center at Memorial Sloan Kettering aims to further define the molecular abnormalities that drive the initiation, maintenance, and progression of every sarcoma type and subtype. This includes genetic, epigenetic, and signaling alterations. It also aims to identify and test molecules that block these changes.
To pursue this, Sarcoma Center investigators are focused on four broad translational research objectives:
- Define shared and type-specific molecular alterations and mechanisms related to the formation of sarcoma, with the goal of identifying and appropriately advancing new rational therapeutic targets and treatments for the various sarcoma subtypes
- Evaluate novel therapies, identifying predictive biomarkers for response and innate and acquired mechanisms of resistance
- Clinically validate new therapeutic targets and treatments in people with sarcoma and facilitate the development, recruitment, and execution of clinical trials that serve both the adult and pediatric populations
- Discover and apply advances in basic science biology and innovative technologies to find, develop, and test new diagnostic and prognostic markers and novel sarcoma therapies
